IP Library Granted Patent US 6,964,951
Granted Patent B2
US 6,964,951 · App. 10/225,418 · Granted Nov 15, 2005

Polynucleotide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,964,951
App. No.
10/225,418
Granted
Nov 15, 2005
Kind
B2
Abstract

The present invention relates to a polynucleotide comprising a ubiquitous chromatin opening element (UCOE) which is not derived from 13. The present invention also relates to a vector comprising the polynucleotide sequence, a host cell comprising the vector, use of the polynucleoticle, vector or host cell in therapy and in an assay, and a method of identifying UCOEs. The UCOE opens chromatin or maintains chromatin in an open state and facilitates reproducible expression of an operably-linked gene in cells of at least two different tissue types.

Claims (15)

1. A method of treatment, comprising administering to a patient in need of such treatment an effective dose of a host cell transfected with a vector comprising a polynucleotide comprising:

a. an element comprising an extended methylation-free CpG-island;

b. an expressible gene, wherein said expressible gene is operably-linked to said CpG-island; and

c. a promoter, operably-linked to said gene, wherein said promoter is not naturally operably-linked to said CpG-island,

wherein said element facilitates reproducible activation of transcription of said gene in two or more tissue types.

2. A method of treatment, comprising administering to a patient in need of such treatment an effective dose of a host cell transfected with a vector comprising a polynucleotide comprising:

a. an element comprising an extended methylation-free CpG-island comprising at least one endogenous promoter;

b. an expressible gene, wherein said expressible gene is operably-linked to said CpG-island, further wherein said expressible gene is not naturally linked to said CpG-island; and

c. a further promoter, external to said CpG-island, operably-linked to said gene, wherein said further promoter is not naturally operably-linked to said CpG-island,

wherein said element facilitates reproducible activation of transcription of said gene in two or more tissue types.

3. A method of treatment, comprising administering to a patient in need of such treatment an effective dose of a host cell transfected with a vector comprising a polynucleotide comprising:

a. an element comprising an extended methylation-free CpG-island comprising at least one endogenous promoter;

b. an expressible gene, wherein said expressible gene is operably-linked to said CpG-island, further wherein said expressible gene is not naturally linked to said CpG-island; and

c. a further promoter, external to said CpG-island, operably-linked to said gene, wherein said further promoter is not naturally operably-linked to said CpG-island,

wherein said element facilitates reproducible activation of transcription of said gene.

Assignments (11)
CHANGE OF ADDRESS Recorded Feb 15, 2018
From: EMD MILLIPORE CORPORATION
To: EMD MILLIPORE CORPORATION
Reel/Frame 045341/0166 →
CHANGE OF NAME Recorded Jan 31, 2012
From: MILLIPORE CORPORATION
To: EMD MILLIPORE CORPORATION
Reel/Frame 027620/0891 →
MERGER Recorded Jan 31, 2011
From: INNOVATA LIMITED
To: MILLIPORE CORPORATION
Reel/Frame 025723/0694 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ALL OF IT - CLIENT WISHES TO RECORD EACH MERGER SEPARATELY. PREVIOUSLY RECORDED ON REEL 019220 FRAME 0355. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER FROM SEROLOGICALS INVESTMENT COMPANY TO FINAL OWNER MILLIPORE CORPORATION.. Recorded Apr 8, 2008
From: SEROLOGICALS INVESTMENT COMPANY
To: SEROLOGICALS ROYALTY COMPANY
Reel/Frame 020762/0580 →
MERGER Recorded Apr 8, 2008
From: SEROLOGICALS FINANCE COMPANY
To: SEROLOGICALS CORPORATION
Reel/Frame 020762/0587 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ALL PATENTS LISTED PREVIOUSLY RECORDED ON REEL 019220 FRAME 0389. ASSIGNOR(S) HEREBY CONFIRMS THE SEROLOGICALS ROYALTY COMPANY MERGER THROUGH TO MILLIPORE CORPORATION. Recorded Apr 8, 2008
From: SEROLOGICALS ROYALTY COMPANY
To: SEROLOGICALS FINANCE COMPANY
Reel/Frame 020762/0592 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ALL PATENTS LISTED PREVIOUSLY RECORDED ON REEL 019220 FRAME 0389. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER FROM SEROLOGICALS ROYALTY COMPANY THROUGH TO MILLIPORE CORPORATION. Recorded Apr 8, 2008
From: SEROLOGICALS CORPORATION
To: MILLIPORE CORPORATION
Reel/Frame 020762/0599 →
MERGER Recorded Apr 27, 2007
From: SEROLOGICALS INVESTMENT COMPANY
To: SEROLOGICALS ROYALTY COMPANY
Reel/Frame 019220/0355 →
MERGER Recorded Apr 27, 2007
From: SEROLOGICALS ROYALTY COMPANY; SEROLOGICALS FINANCE COMPANY; SEROLOGICALS CORPORATION
To: SEROLOGICALS FINANCE COMPANY; SEROLOGICALS CORPORATION; MILLIPORE CORPORATION
Reel/Frame 019220/0389 →
PATENTS AND PATENTS APPLICATIONS Recorded Dec 14, 2005
From: INNOVATA PLC
To: SEROLOGICALS INVESTMENT COMPANY
Reel/Frame 016891/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2004
From: COBRA THERAPEUTICS LIMITED
To: M.L. LABORATORIES PLC
Reel/Frame 014909/0107 →